`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`WOCKHARDT BIO AG,
`TEVA PHARMACEUTICALS USA, INC.,
`AUROBINDO PHARMA U.S.A., INC.,
`Petitioners,
`
`v.
`
`ASTRAZENECA AB,
`Patent Owner.
`
`Case: IPR2015-013401
`U.S. Patent No. RE44,186
`
`
`DECLARATION OF DANIEL M. SILVER IN SUPPORT OF
`PATENT OWNER ASTRAZENECA AB’S UNOPPOSED MOTION FOR
`PRO HAC VICE ADMISSION
`
`
`
`
`
`
`
`1 Petitioner Wockhardt from IPR2016-01029, Petitioner Teva from IPR2016-01122, and
`Petitioner Aurobindo from IPR2016-01117 have been added as Petitioners to this proceeding.
`
`Page 1 of 4
`
`AstraZeneca Exhibit 2216
`Mylan v. AstraZeneca
`IPR2015-01340
`
`
`
`
`
`I, Daniel M. Silver, declare the following:
`
`1.
`
`I am a partner in the law firm of McCarter & English, working in the
`
`firm’s office in Wilmington, Delaware.
`
`2.
`
`I am a member in good standing of the Delaware Bar.
`
`3. My Delaware Bar member number is 4758.
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`I have never had a court or administrative body deny my application
`
`for admission to practice.
`
`6.
`
`I have not applied to appear pro hac vice in any other Patent Trial and
`
`Appeal Board (“PTAB”), or United States Patent and Trademark Office
`
`(“USPTO”), proceeding over the last three years.
`
`7.
`
`I have never had any court or administrative body impose sanctions or
`
`contempt citations against me.
`
`8.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials, as set forth in Part 42 of the
`
`Code of Federal Regulations.
`
`9.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Code of Professional Responsibility set forth in 37 C.F.R. §§ 10.20 et seq., Rules
`
`
`
`Page 2 of 4
`
`
`
`of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq., and disciplinary
`
`jurisdiction under 37 C.F.R. § 11.19(a).
`
`10.
`
`I am an experienced litigation attorney, with experience in many
`
`patent infringement litigations in District Courts, including experience with fact
`
`and expert document and deposition discovery, claim construction, Markman
`
`hearings, motion practice, and trials and hearings.
`
`11.
`
`I am co-counsel for Patent Owner AstraZeneca AB in the ongoing
`
`consolidated litigation captioned AstraZeneca AB v. Aurobindo Pharma Ltd., 14-
`
`cv-00664 (D. Del. 2014) (“the co-pending litigation”) and have been actively
`
`involved in the co-pending litigation, which relates to and involves the same patent
`
`at issue in this proceeding, RE44,186. I am familiar with the subject matter at
`
`issue in this proceeding as a result of my representation of Patent Owner
`
`AstraZeneca AB in the co-pending litigation. For example, I directed and cross-
`
`examiner the financial experts of both parties during the September 2016 trial of
`
`the co-pending litigation. I have significant knowledge of the financial issues that
`
`are relevant to both this proceeding and the co-pending litigation.
`
`12.
`
`I hereby declare that all statements herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledge that willful false
`
`2
`
`Page 3 of 4
`
`
`
`
`
`and the like are punishable by fine, imprisonment, or both, under Section 1001 of
`
`Title 18 of the United States Code.
`
`Dated: November L, 2016
`
`Respectfully Submitted,
`
`niel M. Silver
`MCCARTER & ENGLISH, LLP
`
`Renaissance Centre
`405 N. King St, 8111 Fl.
`Wilmington, DE 19801
`Telephone: (302) 984-6331
`Fax: (302) 691-1260
`dsi1Ver@mccarter.com
`
`
`
`Page 4 of 4
`
`